

AD \_\_\_\_\_

Award Number: DAMD17-99-1-9495

TITLE: Utilization of a NF2-Mutant Mouse Strain to Investigate  
the Cellular and Molecular Function of the NF2 Tumor  
Suppressor, Merlin

PRINCIPAL INVESTIGATOR: Andrea I. McClatchey, Ph.D.

CONTRACTING ORGANIZATION: Massachusetts General Hospital  
Boston, Massachusetts 02114-2696

REPORT DATE: October 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

20040317 045

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> October 2003	<b>3. REPORT TYPE AND DATES COVERED</b> Final (15 Sep 99-14 Sep 03)	
<b>4. TITLE AND SUBTITLE</b> Utilization of a NF2-Mutant Mouse Strain to Investigate the Cellular and Molecular Function of the NF2 Tumor Suppressor, Merlin			<b>5. FUNDING NUMBERS</b> DAMD17-99-1-9495	
<b>6. AUTHOR(S)</b> Andrea I. McClatchey, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Massachusetts General Hospital Boston, Massachusetts 02114-2696  E-Mail: mcclatch@helix.mgh.harvard.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> Original contains color plates. All DTIC reproductions will be in black and white.				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b> Neurofibromatosis type 2 (NF2) is a familial cancer syndrome that features the development of nervous system tumors. The NF2-encoded protein, merlin, localizes to the membrane cytoskeleton interface, which is an unusual physical niche for a tumor suppressor. To generate an animal model for NF2 and to build the foundation for delineating the molecular function of merlin, we established a <i>Nf2</i> -mutant mouse strain through genetic engineering. <i>Nf2</i> <sup>+/-</sup> mice develop a spectrum of tumors that is distinct from that of their human counterparts, including osteosarcomas and hepatocellular carcinomas, which exhibit loss of the wild-type <i>NF2</i> allele. Embryos that are homozygous for a null <i>Nf2</i> mutation fail to gastrulate, while chimeric embryos partially composed of <i>Nf2</i> <sup>-/-</sup> cells develop additional defects, including during cardiac development. Together, these observations indicate a requirement for merlin function in several different cell types in the mouse. The study of <i>Nf2</i> function in these cell types formed the basis of this proposal. The following report describes our accumulating data that indicates an important and general role for NF2 function in cell differentiation. In addition, data from these and other studies in our laboratory point to a general role for merlin function in cell:cell communication in many cell types.				
<b>14. SUBJECT TERMS</b> Neurofibromatosis type 2				<b>15. NUMBER OF PAGES</b> 35
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

**Table of Contents:**

Front page .....	1
Standard Form 298 .....	2
Table of Contents .....	3
Introduction .....	4
Body .....	6-9
Key Research Accomplishments ...	10
Reportable Accomplishments .....	11-12
Conclusions .....	13
References .....	14
Appendices .....	15-20

## **Introduction:**

Neurofibromatosis type 2 (NF2) is a familial cancer syndrome caused by mutation of the *NF2* tumor suppressor gene. Human NF2 patients are predisposed to developing tumors of the central nervous system, particularly schwannomas and meningiomas. The *NF2* gene was cloned nearly a decade ago, but the molecular function of its encoded protein, merlin is not yet known. Merlin localizes to the membrane-cytoskeleton interface, occupying an unusual physical niche for a tumor suppressor. In order to establish the foundation for defining the molecular function of merlin, we have generated a *Nf2*-mutant strain of mice. We found that *Nf2*<sup>+/-</sup> mice, like their human counterparts, are cancer prone but develop a surprising variety of tumor types. Moreover, the tumors that develop in *Nf2*<sup>+/-</sup> mice exhibit a dramatic potential to metastasize, suggesting that the role of *NF2* loss in cancer development may be unappreciated. We also found that *Nf2* function is required for several stages of embryonic development. Thus *Nf2*<sup>-/-</sup> embryos fail immediately prior to gastrulation due to a defect in the extraembryonic lineage. The study of chimeric embryos that are composed of *Nf2*<sup>-/-</sup> and wild-type cells indicated that *Nf2* function is also required for the normal development of several other tissues, including the myocardium and neuroepithelium. Our studies suggest that *Nf2* function is important in many cell types and identifies key cell types for studying *Nf2*-deficiency. The overall goal of this research proposal is to define the signature of *Nf2*-deficiency across several cell types including the ES cell, cardiomyocyte, osteoblast and hepatocyte; each of these cell types is defective when *Nf2*-deficient. Our efforts in this second stage of our research plan have moved forward significantly in the past 12-18 months, guided, in part, by other recently published work from our lab (Lallemand et al., 2003). In these studies we found that merlin localizes to adherens junctions and is required for their formation in mouse embryo fibroblasts (MEFs) and keratinocytes, explaining the lack of contact-dependent inhibition of proliferation exhibited by *Nf2*<sup>-/-</sup> MEFs.

Over the course of this award we have focused on defining the signatures of *Nf2*-deficiency in several cell types: ES cells, cardiomyocytes, osteoblasts and liver cells. Early work revealed that *Nf2*<sup>-/-</sup> ES cells exhibit an altered program of differentiation; thus teratomas derived from *Nf2*<sup>-/-</sup> ES cells contain a limited spectrum of cell types, particularly primitive neuroepithelium and melanocytes. Similarly, embryoid bodies formed from *Nf2*<sup>-/-</sup> ES cells are small and primitive, containing few differentiated cell types. Finally, cultured *Nf2*<sup>-/-</sup> ES cells exhibit limited differentiation potential and cannot form beating cardiomyocytes. This is consistent with our observation that chimeric embryos that are partly composed of *Nf2*<sup>-/-</sup> cells develop tumor-like lesions in the wall of the developing myocardium. These lesions appear to reflect failed cardiomyocyte differentiation, perhaps as a result of abnormal cell:cell communication. We found that in wild-type osteoblasts, merlin levels and phosphorylation are regulated by cell density and cell differentiation, suggesting important roles for merlin in controlling these processes. Indeed, we found that *Nf2* function is required for osteoblast differentiation in vitro and we have begun to evaluate merlin function in osteoblast differentiation and function in



vivo. We also found that merlin is expressed at high levels in hepatocytes and that membrane association of merlin in these cells is regulated by growth factor signaling, suggesting that merlin function is important in hepatocytes. To study merlin function in liver development and tumorigenesis, we generated a liver-specific deletion of *Nf2* in the mouse. These mice develop a dramatic stem-cell lesion that appears to progress and become either hepatocellular carcinoma or cholangiocarcinoma, the two major types of liver cancer.

## **Body**

### ***Nf2* function in osteoblast differentiation.**

Both *Nf2*<sup>+/-</sup> and compound *Nf2*<sup>+/-</sup>;*p53*<sup>+/-</sup> mice spontaneously develop osteosarcomas, suggesting that *Nf2* function is critical for the control of osteoblast proliferation. We have found that merlin levels and phosphorylation are regulated by cell density and differentiation in wild-type osteoblasts. In addition, we found that primary *Nf2*<sup>+/-</sup>;*p53*<sup>+/-</sup> calvarial osteoblasts grow to a higher density in culture and produce more calcified bone than wild-type cultures. However, within a few passages (4-5), these *Nf2*<sup>+/-</sup>;*p53*<sup>+/-</sup> cultures exhibit loss of the wild-type *Nf2* and *p53* alleles and become immortalized. Pure *Nf2*<sup>-/-</sup>;*p53*<sup>-/-</sup> cultures can no longer differentiate, do not undergo density-dependent growth arrest and can form tumors when injected subcutaneously into nude mice. Thus we can recapitulate the genetic basis of tumor development in *Nf2*<sup>+/-</sup>;*p53*<sup>+/-</sup> mice in vitro.

In progress described last year, we examined primary *Nf2*<sup>-/-</sup> osteoblasts isolated from the calvaria of neonatal *Nf2*<sup>loxP/loxP</sup> mice and infected with an adenovirus expressing the Cre-recombinase (Ad-Cre). We found that, like *Nf2*<sup>-/-</sup>;*p53*<sup>-/-</sup> osteoblasts, *Nf2*<sup>-/-</sup> osteoblasts do not differentiate properly, neither expressing osteocalcin nor producing mineralized bone. Thus *Nf2* deficiency alone, prevents osteoblast differentiation in vitro. To determine whether *Nf2* function is similarly required for osteoblast differentiation in vivo, we obtained *α1coll3.6-Cre* transgenic mice, in which expression of the Cre-recombinase should be restricted to developing and mature bone, from Dr. Barbara Kream (UConn). Although *α1collagen* is a marker of the developing skeleton and is expressed at high levels by osteoblasts, these transgenic mice are unpublished and not yet well-characterized. Therefore we first crossed *α1coll-Cre* mice to *ROSA26*<sup>GT</sup> mice that carry a ubiquitously expressed *lacZ* transgene whose expression is inhibited by a 'stuffer' fragment flanked by loxP sites. Cre-mediated recombination removes the 'stuffer', enabling *lacZ* expression; in this way the *ROSA26*<sup>GT</sup> allele serves as a reporter for Cre expression in vivo. Unfortunately, analysis of *α1coll-Cre*;*ROSA26*<sup>GT</sup> mice revealed that in fact, the *α1coll-Cre* transgene was expressed in many tissues during embryonic development and was therefore not suitable for our studies (Figure 1a).

We have now obtained two additional strains of transgenic mice in which the Cre recombinase is expressed under the control of smaller portions of the *α1collagen* promoter and should thus exhibit more restricted Cre expression in bone (*α1coll2.3a-Cre*, from Dr. Barbara Kream and *α1coll2.3b-Cre* from Dr. Henry Kronenberg). We generated *α1coll2.3a-Cre*;*ROSA26*<sup>GT</sup> mice and found that Cre expression is much more tightly restricted to developing bone in *α1coll2.3a-Cre*;*ROSA26*<sup>GT</sup> embryos (Figure 1b). *LacZ* is expressed exclusively in the developing bones at this stage, especially in the craniofacial bones, ribs and limbs. The generation of *α1coll2.3b-Cre*;*ROSA26*<sup>GT</sup> mice and embryos is underway. We have now generated *α1coll2.3a-Cre*;*Nf2*<sup>loxP/loxP</sup> mice and begun to analyze them. Our preliminary results suggest that mice with the *α1coll2.3a-Cre*;*Nf2*<sup>loxP/-</sup> genotype are severely runted while mice of the *α1coll2.3a-Cre*;*Nf2*<sup>loxP/loxP</sup> genotype have 'curly tails' but are otherwise apparently normal. In both cases mineralized bone is

present, suggesting that *Nf2* is not required for bone formation per se in vivo. However, we have not yet determined whether Cre-mediated deletion of *Nf2* in the skeletons of these mice is complete. Preliminary histological analysis of  $\alpha1coll2.3a-Cre;Nf2^{loxP/-}$  mice suggests that the shape and density of osteoblasts lining the trabecular bone is abnormal (not shown). Careful analysis of the skeletons of  $\alpha1coll2.3a-Cre;Nf2^{loxP/-}$  and  $\alpha1coll2.3a-Cre;Nf2^{loxP/loxP}$  mice is underway. Together these studies will allow us to define the function of *Nf2* in osteoblasts in vivo.

Importantly, high cell density and cadherin-mediated cell:cell communication have been shown to be required for osteoblast differentiation. Given our studies in MEFs and keratinocytes, we asked whether merlin is required for adherens junction formation, contact-dependent growth arrest and subsequent differentiation in osteoblasts. We have found that, like MEFs, *Nf2*<sup>-/-</sup> and *Nf2*<sup>-/-</sup>;*p53*<sup>-/-</sup> osteoblasts do not form adherens junctions and do not undergo contact-dependent inhibition of proliferation (Figure 2b,c; not shown). In contrast, both wild-type and *p53*<sup>-/-</sup> osteoblasts make adherens junctions and undergo contact-dependent inhibition of proliferation (Figure 2a,c; not shown), suggesting a mechanism whereby *Nf2*-deficiency prevents osteoblast differentiation. An important goal for the upcoming year is to define the mechanism whereby merlin controls adherens junction formation or stability in both MEFs and osteoblasts; in osteoblasts we will further delineate the link between merlin function and differentiation.

#### ***Nf2* function in hepatocytes.**

Our previous studies revealed that some *Nf2*<sup>+/-</sup> mice develop both hepatocellular carcinoma that exhibits loss of the wild-type *Nf2* allele as well as bile duct carcinoma (cholangiocarcinoma; McClatchey et al., 1998). However, the tumors arise with long latency and their development may be obscured by the frequent development of osteosarcomas in these mice. More recently, Giovannini and colleagues found that *Nf2*<sup>loxP/loxP</sup> mice that were injected retro-orbitally with Ad-Cre developed meningiomas, and at a lower frequency, hepatocellular carcinomas (Kalamarides et al., 2002). We have also found that merlin is associated with hepatocyte membranes and that its membrane distribution is regulated by growth factor stimulation. Thus merlin function appears to be important in liver cells and its loss contributes to liver carcinogenesis in the mouse.

To study merlin function in the liver in vivo, we crossed *Nf2*<sup>loxP/loxP</sup> mice to transgenic mice that express the Cre-recombinase under the control of the liver-specific albumin promoter (*alb-Cre*). We found that by 6-8 weeks of age many *alb-Cre;Nf2*<sup>loxP/loxP</sup> mice exhibit dramatic abdominal swelling due to hepatomegaly. In fact, the livers of these mice often constitute 1/4 to 1/3 of the total body weight of the animal. Other organs appear to be unaffected. Histological examination reveals massive hyperproliferation and infiltration of a relatively undifferentiated cell type in these livers (Figure 3a,b); BrdU labeling reveals a very high mitotic index in these lesions relative to the paucity of dividing cells in the mature liver (Figure 3c,d). The hyperproliferative cells encompass the portal spaces and some of the cells form rudimentary bile duct-like structures, suggesting that the affected cell type is either of the bile duct or stem (oval) cell origin (arrows, Figure 3a,b). Surprisingly, similar lesions are already apparent in the livers of

neonatal mice, suggesting that they are of embryonic in origin and thus may reflect uncontrolled proliferation of liver stem cells (not shown). In fact, the lesions are histologically identical to experimentally induced 'oval cell hyperplasia'. Oval cells are facultative liver stem cells that proliferate and become either cholangiocytes or hepatocytes under certain conditions. We have gathered a panel of markers that should allow us to define the affected cell type in more detail. Preliminary experiments suggest that the undifferentiated cells within the lesions (asterisks) in *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice do not express albumin, cytokeratin 7 (CK7) or cytokeratin 19 (CK19) but do express alpha fetoprotein (AFP; Figure 4a-d). In contrast, the more differentiated bile-duct like cells within the lesions (arrows) do express albumin, CK7 and CK19 but do not express AFP (Figure 4a-d). These observations are consistent with the idea that the lesions that develop in *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice are composed of a mixture of undifferentiated oval cells and cholangiocytes.

The proportion of liver that is involved by hyperplasia in *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice is variable, likely reflecting variability in the proportion of cells in which recombination has occurred. In some mice, all lobes of the liver are involved and few normal hepatocytes remain in the vicinity of the central sinusoid (Figure 3b). These mice do not survive, likely due to loss of normal liver function. Mice that survive past 6-8 weeks of age do so with less involvement of the liver; however, these mice go on to develop multiple liver tumors (Figure 5a). Importantly, aging *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice develop both hepatocellular carcinoma and cholangiocarcinoma (Figure 5b,c). In fact, we frequently found the two different tumors juxtaposed within the same liver (Figure 5d). We hypothesize that this reflects the dual potential of the oval stem cell.

We have established several cell lines from the livers of *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice. These cells form epithelial-like colonies in culture but pile up on top of one another when confluent; they do not undergo contact-dependent inhibition of proliferation (Figure 6a). Western blot analysis reveals that the repertoire of markers expressed by these cell lines mirrors that of the in vivo lesions (not shown). Importantly, adenovirus-mediated reintroduction of *Nf2*-expression leads to morphological flattening of these cells and restoration of contact-dependent inhibition of proliferation (Figure 6b). In contrast, adenoviral reintroduction of a mutant form of merlin carrying a patient-derived missense mutation affects neither morphological flattening nor contact-dependent inhibition of proliferation (Figure 6c).

These results are exciting for several reasons: 1) They provide the foundation for studying *Nf2* function in the liver in vivo; 2) Genetically manipulated mouse models of liver cancer are rare; 3) The possibility that *Nf2* function is important in liver stem cells has important implications for the study of liver disease in humans; and 4) The notion that merlin function is important in liver stem cell differentiation is consistent with our studies of merlin function in other cell types as described above. Although liver cancer is not a recognized feature of human NF2, the disease is quite rare (1/40,000 individuals); therefore a variably penetrant associated phenotype may be difficult to recognize. Moreover, examination the *NF2* gene in human liver cancers has not been undertaken. In fact, loss of chromosome 22q, where the *NF2* locus resides has been detected in several

forms of liver cancer. In addition, the availability of a rare murine model of both hepatocellular carcinoma and cholangiocarcinoma will allow us to study the etiology of both and to identify genetic events that cooperate with *Nf2*-loss in their development.

### ***Nf2* function in cardiomyocyte differentiation.**

We previously found that chimeric embryos that are composed of *Nf2*<sup>-/-</sup>; *lacZ*<sup>+</sup> and wild-type cells develop striking abnormalities in cardiac morphogenesis. Thus *Nf2*<sup>-/-</sup>; *lacZ*<sup>+</sup> cells that contribute to the developing myocardium invariably form tumor-like lesions in the heart wall. This defect is apparent early during cardiac morphogenesis (by E9.5), suggesting that it may reflect a failure of *Nf2*<sup>-/-</sup> cardiomyocyte differentiation. Consistent with this notion, we found that *Nf2*<sup>-/-</sup> ES cells cannot differentiate into beating cardiomyocytes in vitro. Our recent studies in fibroblasts have now suggested an exciting explanation for this defect. In other studies in our laboratory, we have found that the major consequence of *Nf2*-deficiency in primary *Nf2*<sup>-/-</sup> mouse embryo fibroblasts (MEFs) is an inability to undergo contact-dependent inhibition of proliferation and to form cadherin-containing adherens junctions. In fact, we found that merlin colocalizes and associates with cadherin-containing adherens junctions in MEFs. As discussed below, we have found that these are also features of *Nf2*<sup>-/-</sup> osteoblasts and Schwann cells, and thus appear to be signatures of *Nf2*-deficiency. With this in mind, we have re-examined the phenotype associated with *Nf2*-deficiency in the developing heart. The onset of this phenotype in chimeric embryos roughly coincides with the formation of intercalated discs in wild-type cardiomyocytes; intercalated discs are specialized cell:cell junctions that contain adherens junction components. In fact, Kostetskii et al. (2001), recently generated chimeric embryos that are partly composed of N-cadherin-deficient (*N-cad*<sup>-/-</sup>) and wild-type cells; these embryos develop tumor-like lesions in the developing myocardium that are morphologically identical to those that we observe in *Nf2*<sup>-/-</sup>; +/+ embryos. We have generated additional *Nf2*<sup>-/-</sup>; *lacZ*<sup>+</sup>; +/+ embryos and prepared both paraffin and ultrathin sections for immunohistochemical and electron microscopic analysis of the chimeric *Nf2*<sup>-/-</sup> ↔ wt hearts. Our goal is to test the hypothesis that *Nf2*-deficiency leads to defective N-cadherin-mediated cell:cell communication in differentiating cardiomyocytes.

### **Key research Accomplishments:**

- *Nf2*-deficient embryonic stem (ES) cells exhibit abnormal differentiation in the context of teratomas, embryoid bodies and cell cultures. This observation provided the foundation for the study of the role of *Nf2* function in cell differentiation in other cell types. We now know that abnormal differentiation is a signature of *Nf2*-deficiency across many cell types.
- *Nf2*-function is required for cardiomyocyte differentiation in vitro and in vivo. We now believe that this is due to abnormal cell:cell communication.
- *Nf2*-deficiency leads to loss of contact-dependent inhibition of proliferation and loss of adherens junctions in osteoblasts. These phenotypes are also features of *Nf2*-deficient MEFs, Schwann cells and cells derived from *alb-Cre;Nf2<sup>loxP/loxP</sup>* livers and is thus a second signature of *Nf2*-deficiency.
- *Nf2*-deficiency alone leads to failed osteogenic differentiation. Genetic crosses designed to test the requirement for *Nf2* in osteogenic differentiation/function in vivo are complete and histologic analysis is underway.
- Liver-specific deletion of *Nf2* has been achieved by crossing *Nf2<sup>loxP/loxP</sup>* mice with transgenic *alb-Cre* mice. These mice develop hepatomegaly early in life due to the development of invasive lesions that appear to be derived from oval stem cells. Mice with less pervasive lesions live longer and develop both hepatocellular carcinoma and cholangiocarcinoma. A complete analysis of these tumors is underway; cell lines are easily established from these lesions and provide a valuable tool for defining the cellular and molecular function of *Nf2* in the liver. These cells do not undergo contact-dependent inhibition of proliferation; restoration of *Nf2* expression results in morphological flattening and restores contact-dependent inhibition of proliferation.

### **Reportable Outcomes:**

Some of these data have been incorporated into seminar presentations given by Dr. McClatchey at the following meetings:

November, 2002

Invited seminar: NCI Mouse Models Consortium meeting, San Diego, CA.

February, 2003

Invited speaker: AACR Special Conference, Orlando FLA.

March 2003

Abstract selected for presentation: Keystone meeting on Cell Adhesion, Keystone, CO.

June, 2003

Invited speaker: Annual National Neurofibromatosis Foundation Consortium meeting, Aspen, CO.

June, 2002

Invited speaker: Gordon Conference Meeting on 'Cell Proliferation', Colby-Sawyer College, NH.

A manuscript describing a role for merlin in contact-dependent inhibition and adherens junction formation in MEFs was published with cover photo in *Genes & Development*:

Lallemant, D, Curto, M, Saotome, I, Giovannini, M and McClatchey, AI (2003). NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. *Genes Dev.* 17(9): 1090-1100. (attached).

A follow-up manuscript describing persistent growth factor receptor signaling in the absence of cell:cell communication in Nf2-deficient cells has been prepared.

A manuscript describing the requirement for Nf2 function in osteogenic differentiation has been prepared.

A manuscript describing the effects of Ezrin deficiency on mouse intestinal morphogenesis and cell polarization has been prepared and submitted to *Developmental Cell*

The results of this work have formed the basis for the submission of an NIH RO1.

Personnel receiving pay from this research effort:

Andrea I. McClatchey (PI)

Ann Yaktine (Postdoctoral fellow)

Leslie Frieden (Graduate Student)

Marcello Curto (Postdoctoral Fellow)

Ichiko Saotome (senior technician)




## **Conclusions:**

The study of *Nf2*-mutant mice indicates that merlin function is critical in a broad range of cell types. From our efforts to study merlin in several different cell types, two clear themes have emerged: 1) The primary consequence of *Nf2*-deficiency is loss of contact inhibition and loss of stable adherens junctions (this also emerges from our studies of *Nf2*<sup>-/-</sup> MEFs); and 2) Merlin plays an important role in controlling programs of cell differentiation in many lineages. In fact, failed differentiation may be a general mechanism whereby loss of *Nf2* promotes tumorigenesis. For example, our studies of chimeric embryos point to a requirement for *Nf2* function in cardiomyocyte differentiation; in the absence of normal differentiation, these cells form tumor-like lesions in the cardiac wall. We now recognize that this phenotype may be due to abnormal cell:cell communication. Similarly, *Nf2*<sup>-/-</sup> osteoblasts do not form adherens junctions and do not differentiate. We are currently investigating the link between these cellular phenotypes and *Nf2*-associated osteosarcoma development, which is the hallmark of *Nf2*<sup>+/-</sup> mice. These studies have obvious implications for the general study of bone disease in humans. Finally, liver-specific deletion of *Nf2* has yielded an exciting model of primary liver cancer, supporting the idea that merlin functions as a tumor suppressor in this tissue as well. Moreover, preliminary analysis of these lesions suggests that they are of stem cell origin, providing yet another example of a requirement for *Nf2* function in cell differentiation.

## **References:**

- Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann D and Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. *Genes Dev* 2002; 16(9):1060-1065.
- Lallemand D, Curto M, Saotome I, Giovannini M and McClatchey AI. NF2-deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. *Genes Dev.* 2003; 17(9):1090-1100.
- McClatchey AI, Saotome I, Ramesh, V., Gusella JF, Jacks TE. The *Nf2* tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. *Genes & Development* 1997; 11:1253-1265.
- McClatchey AI, Saotome I, Mercer K, Crowley, D, Gusella JF, Jacks TE. Mice with a heterozygous mutation at the *Nf2* tumor suppressor locus a range of highly metastatic tumors. *Genes & Dev.*, 1998; 12(8):1121-1133.
- Shaw RJ, McClatchey AI, Jacks TE. Regulation of the Neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. *J. Biol. Chem.* 1998; 273:7757-7763.
- Shaw RJ, McClatchey AI, Jacks TE. Localization and functional domains of the Neurofibromatosis type II tumor suppressor, merlin. *Cell Growth & Differ.* 1998; 9:287-296.
- Shaw RJ, Paez, JG, Curto M, Pruitt, WM, Saotome I, O'Bryan J, Gupta V, Ratner N, Der C, Jacks T, McClatchey AI. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. *Dev. Cell*, 2001; 1:63-72.
- Saotome I, Curto M and McClatchey AI. Ezrin is required for cell polarization and villus morphogenesis in the developing intestine. Manuscript submitted.
- Curto M, Lallemand D and McClatchey AI. Nf2-deficiency results in persistent growth factor receptor signaling at high cell density. Manuscript prepared.



**A.**




**B.**


*α1coll3.6-Cre;ROSA26<sup>GT</sup>*

*α1coll2.3a-Cre;ROSA26<sup>GT</sup>*

**Figure 1:** By crossing to *ROSA26<sup>GT</sup>* reporter mice and X-gal staining of embryos, we determined that the *α1coll3.6-Cre* transgene is expressed in several tissues including the developing nervous system (E12.5 embryo shown; A). In contrast, the expression of the *α1coll2.3a-Cre* transgene appears to be restricted to bone (E16.5 embryo shown).




**Figure 2:** Immunofluorescent localization of  $\beta$ -catenin reveals the presence of punctate adherens junctions along cell:cell boundaries (arrows) in wild-type (A) but not *Nf2*-deficient (B) primary calvarial osteoblasts. Instead, *Nf2*<sup>-/-</sup> osteoblasts pile up on top of one another.




**Figure 2C:** *Nf2<sup>-/-</sup>* osteoblasts do not undergo contact-dependent inhibition of proliferation. *Nf2<sup>loxP/loxP</sup>* (wild-type) and Ad-Cre infected *Nf2<sup>loxP/loxP</sup>* (*Nf2<sup>-/-</sup>*) primary calvarial osteoblasts were plated at equivalent densities and counted every day for 7 days. Experiments were done in triplicate.

**H&E**




**BrdU**



***Nf2<sup>loxP/loxP</sup>***

***Alb-Cre;Nf2<sup>loxP/loxP</sup>***




**Figure 3:** Hematoxylin and eosin staining of wild-type (A) and *alb-Cre;Nf2<sup>loxP/loxP</sup>* (B) livers in 6-8 week old mice reveals infiltrative lesions that surround the portal spaces (arrows) leaving only small islands of normal hepatocytes in the *alb-Cre;Nf2<sup>loxP/loxP</sup>* livers. BrdU labeling reveals the high mitotic index throughout the *alb-Cre;Nf2<sup>loxP/loxP</sup>* lesions (D). In contrast no cells are labeled in the normal liver (C).



**Figure 4:** Immunohistochemical analysis of markers of liver cells in *alb-Cre;Nf2<sup>loxP/loxP</sup>* livers. The lesions contain both undifferentiated (asterisks) and differentiated (arrows) components. The undifferentiated component of the lesions is composed of cells that do not express albumin, CK7 or CK19 but do express AFP. In contrast some cells within the lesions appear to form primitive bile-duct-like structures; these cells do express albumin, CK7 and CK19 but do express AFP.




A.



**Figure 5:** Older *alb-Cre;Nf2<sup>loxP/loxP</sup>* mice develop multiple frank tumors (A). Some of these tumors are cholangiocarcinomas (B) and some are hepatocellular carcinomas (C) Nearly all of the mice develop both tumor type. For example, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CHC) are juxtaposed in D ( arrows mark boundary between the two).





**Figure 6:** Cells derived from *alb-Cre;Nf2<sup>loxP/loxP</sup>* livers do not undergo contact-dependent inhibition of proliferation (A; mock infected). Adenoviral-mediated reintroduction of merlin leads to a marked flattening of the cells and restores contact-dependent inhibition of proliferation (B). In contrast, adenoviral reintroduction of a mutant version of merlin containing a patient-derived missense mutation (Nf2<sup>L64P</sup>) fails to flatten the cells or restore contact-dependent inhibition of proliferation (C.) A.



# Cell

## & Development

Volume 17 No. 9

May 1, 2003

A JOURNAL OF CELLULAR AND MOLECULAR BIOLOGY

Ro

*Also in this issue:*

- Myc targets in the *Drosophila* and human genome
- GINS, a novel replication complex in *Xenopus* and yeast



Cold Spring Harbor Laboratory Press

C&D 2003

# KODAK IMAGE STATION 2000R



Digital *rad* Imaging

Capture digital images of \_\_\_\_\_, \_\_\_\_\_ and  
markers with the new KODAK Image Station 2000R

- Excellent resolution
- Multiple capture modes
- High sensitivity, low noise
- Plug and play
- Rad Imaging Capability

X-OMAT AR  
film/L+ screen

18 Minute  
Exposure



The Image Station 2000R was developed by Kodak, a world leader in scientific imaging.  
To find out more, visit \_\_\_\_\_ or call: 1-877-SIS-HELP.  
express code 25 (US only) or outside of the US, call +1-203-786-5657. **BEST AVAILABLE**

## KODAK SCIENTIFIC IMAGING SYSTEMS

Kodak is a trademark. © Eastman Kodak Company, 2003.



# ***NF2* deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions**

**Dominique Lallemand,<sup>1</sup> Marcello Curto,<sup>1</sup> Ichiko Saotome,<sup>1</sup> Marco Giovannini,<sup>2</sup>  
and Andrea I. McClatchey<sup>1</sup>**

<sup>1</sup>MGH Cancer Center and Harvard Medical School Department of Pathology, Charlestown, Massachusetts 02129, USA;

<sup>2</sup>INSERM 434, Fondation Jean Dausset-CEPH, 75010, Paris, France

# NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions

Dominique Lallemand,<sup>1</sup> Marcello Curto,<sup>1</sup> Ichiko Saotome,<sup>1</sup> Marco Giovannini,<sup>2</sup> and Andrea I. McClatchey<sup>1,3</sup>

<sup>1</sup>MGH Cancer Center and Harvard Medical School Department of Pathology, Charlestown, Massachusetts 02129, USA;

<sup>2</sup>INSERM 434, Fondation Jean Dausset-CEPH, 75010, Paris, France

**Mutation of the *Neurofibromatosis 2* (NF2) tumor suppressor gene leads to cancer development in humans and mice. Recent studies suggest that *Nf2* loss also contributes to tumor metastasis. The *Nf2*-encoded protein, merlin, is related to the ERM (ezrin, radixin, and moesin) family of membrane:cytoskeleton-associated proteins. However, the cellular mechanism whereby merlin controls cell proliferation from this location is not known. Here we show that the major cellular consequence of *Nf2* deficiency in primary cells is an inability to undergo contact-dependent growth arrest and to form stable cadherin-containing cell:cell junctions. Merlin colocalizes and interacts with adherens junction (AJ) components in confluent wild-type cells, suggesting that the lack of AJs and contact-dependent growth arrest in *Nf2*<sup>-/-</sup> cells directly results from the absence of merlin at sites of cell:cell contact. Our studies indicate that merlin functions as a tumor and metastasis suppressor by controlling cadherin-mediated cell:cell contact.**

[Keywords: NF2; merlin; tumor suppressor; metastasis; cytoskeleton; adherens junction]

Received October 29, 2002; accepted in revised form March 6, 2003.

Neurofibromatosis type 2 (NF2) is a familial cancer syndrome that features the development of multiple nervous system tumors including schwannomas and meningiomas (Gutmann 1997). The disease is caused by inherited heterozygous mutation of the *NF2* tumor suppressor gene; somatic loss of the wild-type allele leads to tumor development. The study of *Nf2*-mutant mice shows that the *NF2* tumor suppressor regulates the proliferation of many cell types and that *Nf2* loss plays a broad role in both tumor development and in tumor metastasis (McClatchey et al. 1997, 1998; Giovannini et al. 2000; Kalamirides et al. 2002). Despite the cloning of the *NF2* gene a decade ago, the molecular function of its encoded protein, merlin, is not yet known. Merlin is a member of the ERM (ezrin, radixin, and moesin) family of proteins that link the actin cytoskeleton to various membrane-associated proteins (Bretscher et al. 2002; Sun et al. 2002). Like the ERM proteins, merlin localizes to the membrane:cytoskeleton interface and thus occupies an unusual physical location for a tumor suppressor. Merlin has been reported to interact with a number of protein partners and to inhibit many signaling pathways when overexpressed (Bretscher et al. 2002; Sun et al.

2002). However, it is not clear which, if any, of the properties of overexpressed merlin are relevant to the tumorigenic consequences of its loss of function.

Somatic loss of *NF2* function is causal to tumor development in mice and humans. Therefore, important clues to the molecular function of merlin can be derived from an analysis of the cellular and molecular consequences of *NF2* deficiency. Although some properties of human *NF2*-deficient tumor cells have been reported, genetically matched control cells are not readily available for comparison (Pelton et al. 1998). The consequences of *Nf2* deficiency in primary cells have not been examined. We previously generated *Nf2*-mutant mice, which are a valuable source of primary *Nf2*-deficient and control cells (McClatchey et al. 1997; Giovannini et al. 2000). In this study, we have carefully examined the properties of primary *Nf2*-deficient mouse embryo fibroblasts (MEFs) and found that they are not transformed and, in fact, are indistinguishable from wild-type MEFs in many ways. However, unlike wild-type MEFs, *Nf2*-deficient MEFs do not undergo contact-dependent inhibition of growth. We found that in both MEFs and in primary epithelial keratinocytes, *Nf2* deficiency leads to defective cadherin-mediated cell:cell adhesion. Merlin localizes to adherens junctions (AJs) and physically interacts with AJ components in confluent wild-type cells, suggesting that merlin normally controls AJ assembly and contact-dependent growth inhibition directly from sites of cell:cell

<sup>3</sup>Corresponding author.

E-MAIL: [mcclatch@helix.mgh.harvard.edu](mailto:mcclatch@helix.mgh.harvard.edu); FAX (617) 726-7808.

Article published online ahead of print. Article and publication date are at <http://www.genesdev.org/cgi/doi/10.1101/gad.1054603>.


contact. These results suggest that loss of AJ function is the cellular mechanism whereby *Nf2* deficiency leads to tumor and metastasis development.

## Results

Heterozygous *Nf2*-mutant mice develop a variety of tumor types, including fibrosarcomas; therefore, we initially studied the growth properties of *Nf2*-deficient primary mouse embryo fibroblasts. We previously determined that both the levels and phosphorylation of merlin are regulated by three conditions in cultured immortalized and primary fibroblasts: high cell density, growth factor withdrawal, and cell:ECM detachment (Shaw et al. 1998; data not shown). Therefore, we asked whether merlin is required for normal growth arrest under these culture conditions. Subconfluent, exponentially growing wild-type and *Nf2*<sup>-/-</sup> MEFs exhibited identical rates of growth and comparable levels of S-phase entry, suggesting that *Nf2* deficiency does not cause an increase in the rate of proliferation of these cells per se (Fig. 1A). However, although wild-type MEFs stopped dividing after reaching confluence, *Nf2*<sup>-/-</sup> MEFs continued to proliferate without saturating (Fig. 1A). In contrast to the monolayer formed by confluent wild-type cells, *Nf2*<sup>-/-</sup> cells formed a multilayer that eventually detached from the culture dish, preventing the measure of later time points. Flow cytometry confirmed that in contrast to wild-type MEFs, a significant percentage of *Nf2*<sup>-/-</sup> MEFs continued to enter S phase after reaching confluence (Fig. 1B). Thus, *Nf2*<sup>-/-</sup> MEFs do not undergo contact-dependent inhibition of proliferation.

Further study revealed that *Nf2*-deficient MEFs are not generally defective in their ability to arrest growth. Both wild-type and *Nf2*<sup>-/-</sup> cultures underwent complete growth arrest after 8 h in suspension or 120 J of UVC irradiation (Fig. 1B). In fact, although a role for merlin function in cell:ECM adhesion has been proposed (Obremski et al. 1998; Shaw et al. 1998; Gutmann et al. 1999; Fernandez-Valle et al. 2002; Johnson et al. 2002), we could not detect obvious cell:ECM adhesion defects in *Nf2*<sup>-/-</sup> MEFs. Thus, both wild-type and *Nf2*<sup>-/-</sup> MEFs attach to and spread on various ECM substrates with comparable kinetics; similarly, focal adhesion formation and density are grossly normal in *Nf2*<sup>-/-</sup> MEFs (data not shown). This is consistent with our observation that *Nf2*<sup>-/-</sup> MEFs are not transformed and cannot form colonies in soft agar or tumors in nude mice (I. Saotome and A. McClatchey, unpubl.). Interestingly, *Nf2*<sup>-/-</sup> MEFs also did not undergo complete growth arrest when serum-starved. Instead, they continued to proliferate slowly, surviving for 2–3 wk without added growth factors (data not shown). Together these data suggest that merlin normally mediates growth arrest specifically under conditions of growth-factor deprivation and cell:cell contact.

The primary phenotype exhibited by *Nf2*<sup>-/-</sup> MEFs was a failure to undergo contact-dependent growth arrest. Examination of key mitogenic signaling pathways in wild-type and *Nf2*<sup>-/-</sup> MEFs at low and high cell density provided a molecular correlation of this growth advantage. As expected given their similar rates of growth, equivalent levels and/or phosphorylation of many signaling proteins were detected in exponentially growing wild-type and *Nf2*<sup>-/-</sup> MEFs (data not shown). In contrast,




**Figure 1.** *Nf2*<sup>-/-</sup> MEFs do not undergo contact-dependent inhibition of proliferation. (A) Wild-type and *Nf2*<sup>-/-</sup> MEFs cultured in the presence of growth factors were counted daily for 5 d. (B) Growth arrest of *Nf2*<sup>-/-</sup> MEFs by high density but not loss of adhesion or UVC-irradiation is impaired. Subconfluent, confluent, suspended, or UVC-treated wild-type and *Nf2*<sup>-/-</sup> MEFs were labeled with BrdU and analyzed by fluorescent-activated cell sorting (FACS) analysis. The graph displays the relative reduction in S phase of wild-type and *Nf2*<sup>-/-</sup> MEFs compared with subconfluent MEFs of the same genotype. Equivalent percentages of wild-type and *Nf2*<sup>-/-</sup> cells remained viable in these experiments (data not shown). FACS analysis also revealed that wild-type and *Nf2*<sup>-/-</sup> MEFs have equivalent cell volumes (data not shown). (C) The level and phosphorylation of key mitogenic signaling molecules were examined in confluent (unstarved) wild-type and *Nf2*<sup>-/-</sup> MEFs by Western blot. Elevated levels of cyclin D, c-jun, and phosphorylated (active) ERK1/2, JNK persist in confluent *Nf2*<sup>-/-</sup> MEFs.



whereas the levels and/or phosphorylation of key signaling proteins markedly diminished after wild-type cells reached confluence, they remained elevated in confluent *Nf2*<sup>-/-</sup> cells, consistent with their persistent proliferation. For example, the levels of cyclin D1, c-jun, phosphorylated ERK1/2, and phosphorylated JNK remained elevated in *Nf2*<sup>-/-</sup> MEFs after reaching confluence (Fig. 1C). Thus, *Nf2*-deficient cells fail to down-modulate mitogenic signaling and continue to proliferate at high cell density.

The ability of confluent *Nf2*<sup>-/-</sup> MEFs to pile up on top of one another, apparently failing to recognize their immediate neighbors, is apparent upon visual inspection (Fig. 2A). Several studies detail a direct role for AJs in contact-dependent inhibition of epithelial cell proliferation (for reviews, see Nollet et al. 2000; Cavallaro and Christofori 2001). Cadherin family adhesion proteins mediate homotypic interaction between adjacent cells and are central to the assembly and function of AJs. Cadherins cluster and recruit intracellular proteins such as catenins ( $\alpha$ -catenin,  $\beta$ -catenin, and p120) and the actin cytoskeleton to AJs (for reviews, see Nagafuchi 2001; Perez-Moreno et al. 2003). AJs have also been identified and studied in fibroblasts by both immunologic and electron microscopic criteria (Yonemura et al. 1995; Gloushankova et al. 1998). To determine whether merlin is involved in the establishment or maintenance of these structures, we examined the expression of AJ components and the assembly of AJs in confluent, wild-type, and *Nf2*<sup>-/-</sup> MEFs. Indeed, both wild-type and *Nf2*<sup>-/-</sup> MEFs express equivalent levels of the core AJ components N-cadherin,  $\alpha$ -catenin, and  $\beta$ -catenin (Fig. 2B). Low levels of E-cadherin were also detected in both wild-type, and *Nf2*<sup>-/-</sup> MEFs (data not shown). In wild-type fibroblasts, indirect immunofluorescence revealed the punctate localization of  $\beta$ -catenin along boundaries of cell-cell contact as has been described (Fig. 2C; Yonemura et al. 1995; Gloushankova et al. 1998). Other AJ components, including N-cadherin, exhibited identical staining (data not shown). In contrast, we never observed AJ-like structures in *Nf2*<sup>-/-</sup> MEFs; instead, all AJ components examined were diffusely localized throughout the membrane despite extensive areas of contact between cells (Fig. 2C, right; data not shown).

To establish that the loss of contact-dependent inhibition of proliferation and loss of AJs were a direct result of the loss of merlin function, we examined the consequences of merlin reintroduction into these cells. We previously found that phosphorylation of C-terminal residue S518 leads to relocalization and inactivation of merlin, whereas an unphosphorylatable mutant (S518A) version functions as a constitutively active protein (Shaw et al. 2001). In MEFs, both endogenous and exogenous merlin are predominantly hyperphosphorylated, suggesting that the availability of active, hypophosphorylated merlin is tightly controlled (data not shown). To ensure that reintroduction of active merlin was achieved, we infected *Nf2*<sup>-/-</sup> MEFs with an adenovirus expressing *Nf2*<sup>S518A</sup> [Ad-*Nf2*<sup>S518A</sup>]. As shown in Figure 2C, *Nf2*<sup>S518A</sup> expression restored both contact-depen-



**Figure 2.** Loss of AJs in *Nf2*<sup>-/-</sup> MEFs. (A) Wild-type and *Nf2*<sup>-/-</sup> MEFs were cultured in the presence of growth factors for 4 d after reaching confluence and photographed by phase contrast. (B) Expression of  $\beta$ -catenin,  $\alpha$ -catenin, and N-cadherin in confluent wild-type and *Nf2*<sup>-/-</sup> MEFs was analyzed by Western blot analysis. (C) Wild-type and *Nf2*<sup>-/-</sup> MEFs were grown to confluence and starved for 48 h. Immunofluorescent localization of  $\beta$ -catenin revealed punctate staining along cell-cell boundaries in wild-type but not *Nf2*<sup>-/-</sup> MEFs. The lower panels show the rescue of both contact-dependent inhibition of proliferation (left) and AJ formation (right) by reintroduction of active merlin (*Nf2*<sup>S518A</sup>). Expression of *Nf2*<sup>S518A</sup> detected by Western blot is shown below.

dent inhibition of proliferation and AJ formation to *Nf2*<sup>-/-</sup> MEFs.


To further test the dependency of AJ formation on merlin function we expressed a dominant-negative form of merlin known as the "Blue Box" mutant (*Nf2*<sup>ΔBB</sup>) in wild-type MEFs (Lafontaine et al. 1996). We found that confluent *Nf2*<sup>ΔBB</sup>-expressing MEFs piled up on top of one another and no longer exhibited punctate localization of AJ components at cell:cell boundaries (Fig. 3A). As predicted of a true dominant negative, *Nf2*<sup>ΔBB</sup> expression had no detectable effect on the phenotype of *Nf2*<sup>-/-</sup> MEFs (data not shown). Thus, expression of a dominant-negative version of merlin mimics *Nf2* deficiency and interferes with the ability of wild-type cells to assemble AJs, confirming the specificity of merlin function in this process.

It has recently been reported that merlin controls contact inhibition of rat schwannoma cells through interaction with CD44 (Morrison et al. 2001). To explore the relationship between merlin and CD44 in MEFs, we measured the ability of *cd44*<sup>-/-</sup> MEFs to undergo contact-dependent inhibition of proliferation. In contrast to *Nf2*<sup>-/-</sup> MEFs, *cd44*<sup>-/-</sup> MEFs stopped proliferating upon

reaching confluence with a saturation density similar to that of wild-type MEFs (Fig. 3B). Moreover, β-catenin localization to cell:cell boundaries in *cd44*<sup>-/-</sup> MEFs was indistinguishable from wild type (Fig. 3A). Therefore, the loss of contact-dependent growth arrest in *Nf2*<sup>-/-</sup> MEFs appears to be CD44-independent.

Finally, to verify that the loss of contact-dependent growth arrest and absence of AJs in *Nf2*<sup>-/-</sup> cells is not simply an indirect consequence of increased mitogenic signaling, we examined MEFs lacking the NF1 tumor suppressor, which is a negative regulator of ras signaling (Cichowski and Jacks 2001). As in other cell types, *Nf1* deficiency in MEFs leads to a proliferative advantage that is likely caused by increased ras signaling (Cichowski et al. 2003; D. Lallemand and A. McClatchey, unpubl.). However, *Nf1*<sup>-/-</sup> MEFs do undergo contact-dependent inhibition of growth and form numerous AJs along cell:cell boundaries (Fig. 3A,B). This is consistent with the observation that ras-transformed Rat-1 fibroblasts also form AJs (Gloushankova et al. 1998). Thus, the lack of AJ formation is specific to loss of merlin function.

Most reports of merlin localization to areas of cortical



**Figure 3.** Expression of dominant-negative merlin (*Nf2*<sup>ΔBB</sup>) disrupts β-catenin localization in wild-type MEFs. (A) Immunofluorescence staining of β-catenin in confluent, serum-starved *cd44*<sup>-/-</sup> MEFs, *Nf1*<sup>-/-</sup> MEFs, or wild-type MEFs infected with an adenovirus expressing *Nf2*<sup>ΔBB</sup>. Expression of dominant-negative merlin disrupts β-catenin localization in wild-type cells (top right). In contrast, β-catenin localizes normally in *cd44*<sup>-/-</sup> (bottom left) or *Nf1*<sup>-/-</sup> (bottom right) MEFs. Expression of *Nf2*<sup>ΔBB</sup> in *Nf2*<sup>-/-</sup> MEFs was demonstrated by Western blot using an anti-merlin antibody (right). (B) *cd44*<sup>-/-</sup> and *Nf1*<sup>-/-</sup> MEFs exhibit contact-dependent inhibition of growth. *cd44*<sup>-/-</sup> (two independently prepared populations, A and B) and *Nf1*<sup>-/-</sup> MEFs were seeded at a subconfluent density in the presence of growth factors and counted daily. After 4–5 d, MEFs of both genotypes reached saturation and stopped proliferating.




cytoskeletal remodeling such as membrane ruffles describe studies performed in subconfluent cells (Sun et al. 2002); however, merlin also localizes to areas of cell:cell contact in vivo in *Drosophila* and in cultured mammalian cells (McCartney and Fehon 1996; Maeda et al. 1999). To determine whether the lack of AJs in *Nf2*<sup>-/-</sup> MEFs is a direct consequence of the absence of merlin from that location, we examined the localization of merlin in confluent wild-type MEFs by immunofluorescence. We detected precise colocalization of endogenous merlin with several AJ components, including  $\beta$ -catenin, N-cadherin, and  $\alpha$ -catenin in punctate structures along borders of cell:cell contact (Fig. 4A; data not shown).


The possibility that merlin physically associates with AJ components was tested by immunoprecipitating merlin from confluent wild-type MEFs using two different anti-merlin antibodies; subsequent Western blotting revealed coimmunoprecipitation of  $\beta$ -catenin with merlin using either antibody (Fig. 4B, lanes 2,3). It is notable that these proteins were coimmunoprecipitated from the soluble membrane fraction, which contains only a small pool of merlin (Fig. 5A). We were unable to develop satisfactory conditions for immunoprecipitating merlin from the Triton-insoluble membrane fraction. In fact, we would predict that active hypophosphorylated merlin, which is underrepresented in the soluble fraction, preferentially interacts with  $\beta$ -catenin. Thus the data shown

in Figure 4B may substantially underrepresent the magnitude of association between these two proteins. Notably, although merlin has been reported to interact with paxillin (Fernandez-Valle et al. 2002), we could not detect colocalization, cofractionation, or coimmunoprecipitation of merlin with paxillin in MEFs (Fig. 5A; data not shown). Together these data indicate that merlin associates with  $\beta$ -catenin at sites of cell:cell contact; loss of merlin from this location may directly impair the formation or stability of AJs, leading to loss of contact-dependent inhibition of growth.

To explore the mechanistic relationship between merlin and AJs, we examined the subcellular distribution of AJ components in *Nf2*<sup>-/-</sup> MEFs. We found that the distribution of AJ components among cytosolic, soluble membrane and insoluble membrane compartments was unaltered in *Nf2*<sup>-/-</sup> MEFs (Fig. 5A). In fact, core AJ complexes can be immunoprecipitated from the membrane of *Nf2*<sup>-/-</sup> cells at wild-type levels and stoichiometry (Fig. 5B). However, under conditions in which the cytosolic compartment has been depleted and membranes have been preserved, immunofluorescent localization of these components reveals diffuse distribution throughout the membrane of *Nf2*<sup>-/-</sup> cells (Figs. 2C, 3A). Therefore, loss of merlin does not prevent membrane localization or retention of the AJ core complex; instead, merlin appears to be required to assemble or stabilize the final AJ structure.



**Figure 4.** Merlin and  $\beta$ -catenin colocalize and associate with AJ components. (A) Localization of merlin (red) in confluent wild-type MEFs along a boundary of cell:cell contact (arrows; 20 $\times$  magnification). Nuclei are stained with DAPI (blue). (B) Colocalization of merlin (red, arrows in left panel) and  $\beta$ -catenin (green, middle) in confluent wild-type MEFs at sites of cell:cell contact (merge, right panel; 40 $\times$  magnification). This staining is not detectable in *Nf2*<sup>-/-</sup> MEFs (data not shown). (C) Immunoprecipitation of  $\beta$ -catenin (lane 1) and merlin (N-terminal epitope, lanes 2,4; C-terminal epitope, lanes 3,5) from the membrane soluble fraction of wild-type (left panel) and *Nf2*<sup>-/-</sup> (right panel) MEFs, followed by Western blot (WB) analysis using anti- $\beta$ -catenin (upper panel I) or anti-merlin (lower panel II) antibodies. (Lane 6) Total membrane soluble fraction from *Nf2*<sup>-/-</sup> MEFs. In wild-type MEF membranes,  $\beta$ -catenin coimmunoprecipitates with merlin using both anti-merlin antibodies. As expected,  $\beta$ -catenin was not detected when immunoprecipitations from *Nf2*<sup>-/-</sup> membranes were performed using anti-merlin antibodies (lanes 4,5).



**Figure 5.** Core AJ complexes form in *Nf2*<sup>-/-</sup> MEF membranes. (A) Merlin and AJ component distribution in cytosolic (C), membrane soluble (S), and membrane insoluble (I) fractions from confluent, serum-starved wild-type (left) and *Nf2*<sup>-/-</sup> (right) MEFs. The distribution of AJ components is identical in wild-type and *Nf2*<sup>-/-</sup> MEFs. Merlin is largely insoluble and cofractionates with β-catenin but not paxillin. (B) Equivalent levels of β-catenin coimmunoprecipitate with N-cadherin, E-cadherin, β-catenin, p120 catenin, or α-catenin from confluent wild-type and *Nf2*<sup>-/-</sup> membranes.

Although their existence has been well documented in fibroblasts, AJ formation has been more thoroughly studied in epithelial cells. We therefore asked whether merlin is also required for AJ formation in primary epithelial mouse keratinocytes in which AJ assembly and disassembly can be controlled by modulating extracellular calcium levels (Vasioukhin et al. 2000). As shown in Figure 6A, in high Ca<sup>2+</sup>-containing medium, endogenous merlin precisely colocalizes with AJ components along cell:cell boundaries in these cells. To examine the localization of merlin in real time, we transfected wild-type primary keratinocyte cultures with a plasmid expressing a GFP-merlin fusion protein (GFP-Nf2<sup>wt</sup>). Like endogenous merlin, GFP-Nf2<sup>wt</sup> colocalizes with AJ compo-


nents along developing and mature cell:cell boundaries (Fig. 6B).

To determine whether localization to AJs is critical for the tumor suppressor function of merlin, we expressed a version of merlin carrying a rare patient-derived missense mutation (GFP-Nf2<sup>L64P</sup>) in primary keratinocytes. This mutation is known to abrogate the growth-suppressing function of merlin; however, the subcellular localization of Nf2<sup>L64P</sup> has not been evaluated (Gutmann et al. 1998; Morrison et al. 2001). In striking contrast to wild-type merlin, GFP-Nf2<sup>L64P</sup> exhibited a strong punctate distribution throughout the cytoplasm (Fig. 6C, right). Interestingly, at early time points after transfection (12 h), a small fraction of GFP-Nf2<sup>L64P</sup> did localize to cell:cell boundaries, suggesting that the mutation does not lead to gross mislocalization of merlin but, rather, prevents retention of merlin to AJs (Fig. 6C, left). Notably, AJs form normally in wild-type keratinocytes that produce GFP-Nf2<sup>L64P</sup> (data not shown); thus, GFP-Nf2<sup>L64P</sup> does not function as a dominant-negative version of merlin. Together, these data suggest that stable localization to cell:cell boundaries is important for the growth-suppressing function of merlin.

Finally, we examined the formation of AJs in Ad-Cre-infected primary keratinocytes from newborn *Nf2*<sup>flox2/flox2</sup> mice. After Ad-Cre infection (3 d), cells were switched to high calcium to stimulate AJ formation. In wild-type cells at early time points after calcium induction (3–6 h), actin-containing zipper-like structures formed along cell:cell boundaries as has been described (Vasioukhin et al. 2000). These structures subsequently resolved into continuous zones of adhesion containing actin and AJ components (Fig. 6D). In contrast, Ad-Cre-infected keratinocytes did not form adhesion zippers at early time points after calcium induction (data not shown). Instead, they became misshapen, losing the integrity of the cortical actin ring and exhibiting diffuse membrane localization of AJ components. Even 20 h after calcium induction, zones of adhesion were rarely, if ever, apparent in *Nf2*<sup>-/-</sup> keratinocytes, despite extensive physical contact between cells (Fig. 6D). Thus, as in fibroblasts, merlin function is required for the formation or stabilization of AJs in primary epithelial cells.

## Discussion

Recent studies suggest that inactivation of the NF2 tumor suppressor merlin plays a broad role in cancer development and progression in humans and in mice (McClatchey et al. 1998). Insight into the basis of this awaits the definition of the molecular function of merlin. Here, we provide the first analysis of the phenotype associated with *Nf2* loss of function in primary cells. We found that the primary phenotypic consequence of *Nf2* deficiency is loss of contact-dependent inhibition of growth. Several lines of evidence suggest that this phenotype is due to a lack of AJ formation or maintenance. First, *Nf2*<sup>-/-</sup> MEFs do not form AJs, despite normal expression and membrane localization of AJ components. Second, reintroduction of active merlin restores both contact-dependent in-



**Figure 6.** Merlin localization in primary keratinocytes. (A) Confluent wild-type keratinocytes were cultured in the presence of 2 mM  $\text{CaCl}_2$  for 20 h to stimulate the formation of AJs. Immunostaining revealed perfect colocalization of endogenous merlin (red) and  $\beta$ -catenin (green; merge, yellow). (B) A GFP-Nf2 (wild-type) fusion protein (green; middle) colocalizes with E-cadherin (red) to a region of nascent cell:cell contact in wild-type primary keratinocytes (merge, yellow). Transfection of the GFP-Nf2-expressing plasmid and calcium induction were carried out simultaneously; 24 h later, cells were fixed, permeabilized, and processed for immunofluorescence. (C) A mutant GFP-Nf2<sup>L64P</sup> version of merlin exhibits limited localization to cell:cell boundaries at early times (12 h) after transfection, but at late times (48 h) after transfection, GFP-Nf2<sup>L64P</sup> exhibits only punctate, cytoplasmic localization. Nuclei are stained with DAPI (blue). (D) In a wild-type keratinocyte monolayer (upper panels),  $\beta$ -catenin localizes precisely to cell:cell boundaries (right panel). In contrast, in Nf2<sup>-/-</sup> keratinocytes (bottom panels),  $\beta$ -catenin is diffusely localized throughout the cell. In addition, rhodamine-phalloidin staining (left panels) reveals that the cortical actin ring is malformed and badly disorganized in Nf2<sup>-/-</sup> keratinocytes.

hibition of growth and AJ formation to Nf2<sup>-/-</sup> MEFs. Third, a dominant-negative version of merlin confers loss of AJ formation to wild-type MEFs. Fourth, merlin colocalizes and associates with AJ components. Finally, a patient-derived missense mutation abolishes both the

growth-suppressing function and AJ localization of merlin. The importance of merlin function in AJ establishment was confirmed in primary epithelial keratinocytes, a prototypical system for the study of AJs. Importantly, loss of contact-dependent inhibition of growth and lack

of AJs appear to be signatures of *Nf2* deficiency as these properties are also exhibited by primary *Nf2*<sup>-/-</sup> mouse osteoblasts, which are target cells for tumor development in *Nf2*<sup>+/-</sup> mice (A.I. McClatchey, D. Lallemand, and M. Loeffler, unpubl.).

Our data suggest a model whereby merlin stabilizes the link between the AJ and the actin cytoskeleton. It has been demonstrated that prior to AJ assembly, core AJ complexes, many of which are already tethered to the actin cytoskeleton, are diffusely localized throughout the plasma membrane (Adams et al. 1998; Sako et al. 1998). Upon heterotypic interaction, cadherin complexes cluster via lateral movement, concomitant with strengthened cytoskeletal interaction. The presence of apparently normal levels of diffusely localized core AJ complexes in the membranes of *Nf2*<sup>-/-</sup> cells suggests that merlin is required for this late step in assembling or stabilizing the final AJ structure.

The establishment and maturation of AJs has been best studied in epithelial cells, where it is clear that this is a complex and dynamic process that begins with the initial establishment of contact between adjacent membranes. A nascent AJ then serves as a nucleus from which the development of new AJs progresses outward, sealing the two membranes (Vasioukhin et al. 2000; Ehrlich et al. 2002). The actin cytoskeleton is required for this process (Angres et al. 1996; Vaezi et al. 2002). In epithelial cells, interdependency between the cortical actin ring and AJ establishment has been demonstrated (Adams et al. 1998; Quinlan and Hyatt 1999). We show here that merlin localizes to AJs and associates with AJ components. Merlin has also been reported to physically interact with and stabilize actin filaments in vitro (James et al. 2001). Thus, merlin may function to locally stabilize actin filaments at the site of AJs. Consistent with this idea, we found that loss of merlin in primary keratinocytes led to disruption of the cortical actin ring and disruption of AJs.

We have recently demonstrated a reciprocal relationship between merlin and Rac, a member of the Rho family of GTPases, key regulators of the actin cytoskeleton (for review of Rho GTPases, see Hall 1998; Shaw et al. 2001). Thus, Rac activation leads to phosphorylation and inactivation of merlin; conversely, active merlin can negatively regulate Rac-induced signaling and cell transformation (Shaw et al. 2001). Several studies establish a dynamic relationship between Rac activity and AJ assembly and stabilization (Fukata and Kaibuchi 2001; Lambert et al. 2002; Yap and Kovacs 2003). It has recently been demonstrated that Rac is physically recruited to sites of nascent AJ assembly and then is removed quickly as maturation proceeds (Ehrlich et al. 2002). In contrast, both constitutively active (S518A) and inactive (S518D) forms of merlin can localize to AJs (D. Lallemand and A. McClatchey, unpubl.). Therefore, Rac may be transiently recruited to nascent AJs to locally inhibit merlin function and facilitate actin remodeling at developing AJs. Subsequent loss of Rac-mediated inhibition of merlin, together with reactivation, perhaps via the activity of a phosphatase, would stabilize the final AJ

structure. Active AJ-associated merlin would then maintain low local levels of active Rac. This is consistent with our observation that the levels of active hypophosphorylated merlin are markedly increased in confluent fibroblasts (Shaw et al. 1998). This model predicts that in the absence of merlin, AJs would not be stabilized.

Consistent with the idea that merlin stabilizes the interaction between the AJ and actin cytoskeleton, there are striking similarities between merlin and  $\alpha$ -catenin. Deletion of  $\alpha$ -catenin in murine keratinocytes leads to defective AJ formation, loss of contact-dependent inhibition of proliferation, and the development of tumor-like lesions in vivo (Vasioukhin et al. 2001). In fact, as in *Nf2*<sup>-/-</sup> cells, AJ components do exhibit membrane localization in  $\alpha$ -catenin-null keratinocytes; like *Nf2*<sup>-/-</sup> cells,  $\alpha$ -catenin-null cells also exhibit altered actin organization (Vasioukhin et al. 2001). Merlin, like  $\alpha$ -catenin, may be a key element linking cadherin-containing complexes to the actin cytoskeleton. Actin-controlled assembly of macromolecular complexes at the cell periphery represents a novel mechanism of tumor-suppressor function.

It has recently been proposed that metastatic potential may be conferred by the nature of early or initiating tumor mutations rather than by secondary mutation of metastasis-specific genes (Bernards and Weinberg 2002). *Nf2* is a clear example of a gene that, when mutated, can contribute to both tumor initiation and progression, depending on the tumor type. Schwannomas are generally slow-growing, benign tumors that rarely metastasize, regardless of their genotype. In contrast, *Nf2*<sup>+/-</sup> mice develop a variety of tumors that are highly metastatic (McClatchey et al. 1998). Loss of AJ function has been firmly linked to both tumor development and tumor invasion in many systems (for review, see Cavallaro and Christofori 2001). Finally, the ability of *Nf2*<sup>-/-</sup> cells to grow slowly in the absence of added growth factors may provide a unique advantage for successful late-stage metastatic colonization. We suggest that the unique cocktail of growth advantages exhibited by *NF2*-deficient cells explains the tumorigenic and often metastatic consequences of its loss. Merlin function is critical in many cell types in the mouse, suggesting that merlin inactivation by genetic or other means may be a key step in the development of many types of cancer.

## Materials and methods

### Cell culture

We examined the consequences of both constitutional and acute deletion of *Nf2* in MEFs by harvesting primary MEF populations from either embryonic day 12.5 (E12.5) chimeric *Nf2*<sup>-/-</sup> embryos or *Nf2*<sup>lox2/lox2</sup> embryos. Selection of *Nf2*<sup>-/-</sup> MEFs from chimeric embryos has been described (Shaw et al. 2001). Wild-type MEF populations selected from chimeric embryos partially composed of neomycin-resistant wild-type cells were used as controls. Alternatively, *Nf2*<sup>lox2/lox2</sup> MEFs were infected with an adenovirus expressing the Cre recombinase (Ad5CMV-Cre). Mock-infected *Nf2*<sup>lox2/lox2</sup> MEFs were processed in parallel. Greater than 90% recombination efficiency was achieved as assessed by Western blot and PCR analysis

(data not shown). Wild-type (un-Cre-able) MEFs infected with Ad-Cre did not exhibit a detectable phenotype in our assays (data not shown). After establishing that *Nf2<sup>-/-</sup>* MEFs isolated by either method exhibited identical growth properties, we used Ad-Cre and mock-infected *Nf2<sup>fllox2/fllox2</sup>* MEFs for subsequent experiments. Primary MEFs were used between passages 2 and 5. *cd44<sup>-/-</sup>* and *Nf1<sup>-/-</sup>* MEFs were isolated from E12.5 *cd44<sup>-/-</sup>* or *Nf1<sup>-/-</sup>* embryos.

The protocol for mouse keratinocyte preparation was kindly provided by Stuart Yuspa (NCI) and modified slightly. Briefly, after sacrifice, newborn (P1–P2) mouse skin was removed and placed into calcium-free trypsin overnight (4°C). The following day, the epidermis was separated from the dermis and disaggregated in keratinocyte media (GIBCO-BRL) containing 1.4 mM  $\text{CaCl}_2$ . After a brief centrifugation, the cells were resuspended in keratinocyte media containing 4 ng/mL EGF, 25  $\mu\text{g}$  of bovine pituitary extract, and 0.2 mM  $\text{CaCl}_2$  and seeded onto coverslips. The following day, the concentration of calcium in the media was lowered to 0.05 mM. For AJ induction, calcium was raised to 2 mM for 20 h. Ad-Cre infection of keratinocytes was performed as for MEFs.

#### Adenovirus production and infection

Ad5CMV-Cre was purchased from University of Iowa Gene Transfer Vector Core. The Blue Box (*Nf2<sup>ΔRB</sup>*), *Nf2<sup>5518A</sup>*, and *Nf2<sup>L64P</sup>* mutants were created by site-directed mutagenesis of mouse *Nf2* isoform 1 (QuikChange, Stratagene) in pcDNA3. All constructs were sequenced in their entirety. The *Nf2<sup>ΔRB</sup>*-expressing adenovirus was prepared using the Adeasy system (Stratagene) according to the manufacturer. Infections were performed overnight at a concentration of 50 m.o.i./cell.

#### GFP-fusion constructs

Wild-type and L64P-containing mouse *Nf2* cDNAs were cloned in-frame into pEGFP-C1 expression vectors to create N-terminal GFP-fusions (Clontech). Keratinocytes were transfected using Lipofectamine Plus (GIBCO-BRL).

#### Proliferation analysis

For cell growth curves,  $4 \times 10^4$  MEFs were seeded in triplicate in 15-mm wells in DME + 10% FBS. Beginning the following day (day 1), cells were trypsinized and counted daily. Experiments were repeated at least three times using multiple preparations of MEFs. For FACS analysis, MEFs were either maintained in DME + 10% FBS for 48 h after reaching confluence, suspended in DME + 10% FBS for 16 h, or maintained in DME + 10% FBS for 24 h after 120 J of UVC, labeled with BrdU (10 mM, 4 h), and collected and processed according to the manufacturer (Becton-Dickinson). Briefly, cells were fixed in 70% ethanol and treated with 2 N HCl in 0.5% Triton X-100. After neutralization with 0.1 M  $\text{Na}_2\text{B}_4\text{O}_7$  (pH 8.5), MEFs were sequentially incubated with an anti-BrdU antibody (Becton-Dickinson; 30 min) and FITC-conjugated horse anti-mouse secondary antibody (Vector Laboratories; 30 min). Cells were resuspended in PBS containing 40  $\mu\text{g}/\text{mL}$  propidium iodide and RNase. Analysis was performed with CellQuest software (Becton-Dickinson).

#### Protein analysis

Total protein extracts were prepared in modified RIPA lysis buffer (50 mM Tris at pH 7.4, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM  $\text{Na}_3\text{VO}_4$ , 10 mM NaF, 10 mM  $\beta$ -glycerophosphate, 1 mM EDTA at pH 8.0, 1 mM

EGTA, and protease inhibitors). For membrane extracts, cells were lysed by mechanical disruption in cold hypotonic buffer (10 mM HEPES at pH 7.4, 1 mM EDTA, and protease inhibitors). Nuclei were pelleted by centrifugation at 750g for 10 min. Further centrifugation of the resulting supernatant at  $1 \times 10^5\text{g}$  for 1 h led to recovery of the cytosolic fraction (C). The pellet was extracted with membrane extraction buffer (MEB; 50 mM Tris at pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM  $\text{Na}_3\text{VO}_4$ , and protease inhibitors) and centrifuged at  $1 \times 10^5\text{g}$  for 1 h. This supernatant corresponded to the Triton X-100 soluble membrane extract (S). The final pellet was extracted with modified RIPA buffer and centrifuged at  $1 \times 10^5\text{g}$  for 5 min; this supernatant corresponded to the Triton X-100 insoluble fraction (I). Equal quantities of protein were separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed at 4°C overnight in PBS, 0.05% Tween-20, and 5% nonfat dry milk or 1% BSA for phospho-specific antibodies.

#### Antibodies

The primary antibodies used were from Santa Cruz (anti-merlin: sc331, sc332, 1:500 dilution; anti-JNK1: sc474, 1:1000), Cell Signaling (anti-ERK1/2: 9102; anti-phosphoERK1/2: 9101; anti-phospho-JNK: 9255, all at a 1:500 dilution), Sigma (anti-tubulin: T9026), Zymed (anti-E-cadherin: 13-1900), and Transduction Labs (anti- $\beta$ -catenin: C19220; anti- $\alpha$ -catenin: C21620; anti-N-cadherin: C70320; anti-paxillin: P13520; anti-P120: P17920). Antibodies to c-jun and cyclin D1 were gifts from M. Yaniv (Institute Pasteur, Paris, France) and E. Harlow (Harvard Medical School, Boston, MA), respectively. HRP-linked secondary antibodies to rabbit, mouse, or rat were from Amersham.

#### Indirect immunofluorescence

Confluent, serum-starved wild-type MEFs were simultaneously permeabilized and fixed as follows: Cells plated on coverslips were incubated in 1% paraformaldehyde, 0.1% Triton X-100, 0.1% NP-40 in 2.5 mM triethanolamine for 30 min. Cells were then further permeabilized in 0.5% Triton X-100 in PBS for 10 min. Coverslips were blocked in PBS + 0.2% BSA and incubated with anti- $\beta$ -catenin (1:200), anti-merlin (sc332; 1:50), or anti-E-cadherin (1:250) primary antibodies at 4°C overnight in PBS + 0.2% BSA. Coverslips were rinsed five times with PBS and incubated with secondary antibodies in PBS + 0.2% BSA. FITC- and rhodamine-conjugated secondary anti-mouse, anti-rabbit, and anti-rat antibodies were purchased from Calbiochem or ICN (anti-rat). Coverslips were mounted using Vectashield (Vector Labs). Photographs were taken at 20 $\times$  with a Nikon Microphot epifluorescence microscope.

#### Immunoprecipitation

For immunoprecipitation, 200  $\mu\text{g}$  of Triton X-100 soluble membrane extract was precleared at 4°C for 1 h with 20  $\mu\text{L}$  of protein-G Sepharose (Pharmacia) and 2  $\mu\text{g}$  of either mouse or rabbit nonspecific IgG (Sigma) in a final volume of 500  $\mu\text{L}$  of MEB. After quick centrifugation, the supernatant was incubated at 4°C for 2 h with 20  $\mu\text{L}$  of protein-G Sepharose and 2  $\mu\text{g}$  of anti-merlin (sc331, sc332), anti- $\beta$ -catenin, anti- $\alpha$ -catenin, P120, anti-E-cadherin, or anti-N-cadherin antibodies. The beads were washed five times in cold MEB and resuspended in 50  $\mu\text{L}$  of 1 $\times$  Laemmli SDS sample buffer.

#### Acknowledgments

We thank Nick Dyson, Spyros Artavanis-Tsakonas, and Jeff Settleman for critical reading of the manuscript, Jim Rocco and



members of his laboratory for help with adenovirus preparation, Ivan Stamenkovic for the *cd44*<sup>-/-</sup> mice, and Brett Johnson and Raphaella Sordella for useful discussions and reagents. We thank Stuart Yuspa and Ulriche Lichti for helpful advice in isolating and culturing primary murine keratinocytes. We gratefully acknowledge members of the McClatchey laboratory for helpful discussions throughout. This study was supported by the American Cancer Society, the Department of Defense Neurofibromatosis Program (A.I.M.), Ligue Contre le Cancer (M.G.), and the National Neurofibromatosis Foundation and Association pour la Recherche Contre le Cancer (D.L.).

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

## References

- Adams, C.L., Chen, Y.T., Smith, S.J., and Nelson, W.J. 1998. Mechanisms of epithelial cell:cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. *J. Cell Biol.* **142**: 1105-1119.
- Angres, B., Barth, A., and Nelson, W.J. 1996. Mechanism for transition from initial to stable cell-cell adhesion: Kinetic analysis of E-cadherin-mediated adhesion using a quantitative adhesion assay. *J. Cell Biol.* **134**: 549-557.
- Bernards, R. and Weinberg, R.A. 2002. A progression puzzle. *Nature* **418**: 823.
- Bretscher, A., Edwards, K., and Fehon, R.G. 2002. ERM proteins and merlin: Integrators at the cell cortex. *Nat. Rev. Mol. Cell Biol.* **3**: 586-599.
- Cavallaro, U. and Christofori, G. 2001. Cell adhesion in tumor invasion and metastasis: Loss of the glue is not enough. *Biochim. Biophys. Acta* **1552**: 39-45.
- Cichowski, K. and Jacks, T. 2001. NF1 tumor suppressor gene function: Narrowing the GAP. *Cell* **104**: 593-604.
- Cichowski, K., Santiago, S., Jardim, M., Johnson, B.W., and Jacks, T. 2003. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. *Genes & Dev.* **17**: 449-454.
- Ehrlich, J.S., Hansen, M.D.H., and Nelson, J.W. 2002. Spatiotemporal regulation of Rac1 localization and lamellipodial dynamics during epithelial cell:cell adhesion. *Dev. Cell* **3**: 259-270.
- Fernandez-Valle, C., Tang, Y., Ricard, J., Rodenas-Ruano, A., Taylor, A., Hackler, E., Biggerstaff, J., and Iacovelli, J. 2002. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. *Nat. Genet.* **3**: 354-362.
- Fukata, M. and Kaibuchi, K. 2001. Rho-family GTPases in cadherin-mediated cell-cell adhesion. *Nat. Rev. Mol. Cell Biol.* **2**: 887-896.
- Giovannini, M., Robanus-Maandag, E., van der Valk, M., Niwa-Kawakita, M., Abramowski, V., Goutebroze, L., Woodruff, J.M., Berns, A., and Thomas, G. 2000. Conditional biallelic *Nf2* mutation in the mouse promotes manifestations of human neurofibromatosis type 2. *Genes & Dev.* **14**: 1617-1630.
- Gloushankova, N.A., Krendel, M.F., Alieva, N.O., Bonder, E.M., Feder, H.H., Vasiliev, J.M., and Gelfand, I.M. 1998. Dynamics of contacts between lamellae of fibroblasts: Essential role of the actin cytoskeleton. *Proc. Natl. Acad. Sci.* **95**: 4362-4367.
- Gutmann, D.H. 1997. Molecular insights into neurofibromatosis 2. *Neurobiol. Dis.* **3**: 247-261.
- Gutmann, D.H., Geist, R.T., Xu, H.-M., Kim, J.S., and Saporito-Irwin, S. 1998. Defects in Neurofibromatosis 2 protein function can arise at multiple levels. *Hum. Mol. Genet.* **7**: 335-345.
- Gutmann, D.H., Sherman, L., Seftor, L., Haipek, C., Hoang, L.K., and Hendrix, M. 1999. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. *Hum. Mol. Genet.* **8**: 267-275.
- Hall, A. 1998. Rho GTPases and the actin cytoskeleton. *Science* **279**: 509-514.
- James, M.F., Manchanda, N., Gonzalez-Agosti, C., Hartwig, J.H., and Ramesh, V. 2001. The Neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. *Biochem. J.* **356** (Pt2): 377-386.
- Johnson, K.C., Kissil, J.L., Fry, J.L., and Jacks, T. 2002. Cellular transformation by a FERM domain mutant of the *Nf2*-tumor suppressor gene. *Oncogene* **21**: 5990-5997.
- Kalamirides, M., Niwa-Kawakita, M., Leblois, H., Abramowski, V., Perricaudet, M., Janin, A., Thomas, G., Gutmann, D.H., and Giovannini, M. 2002. *Nf2* gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. *Genes & Dev.* **16**: 1060-1065.
- LaJeunesse, D.R., McCartney, B.M., and Fehon, R.G. 1996. Structural analysis of *Drosophila* merlin reveals functional domains important for growth control and subcellular localization. *J. Cell Biol.* **141**: 1589-1599.
- Lambert, M., Choquet, D., and Mege, R.-M. 2002. Dynamics of ligand-induced, Rac1-dependent anchoring of cadherins to the actin cytoskeleton. *J. Cell Biol.* **157**: 469-479.
- Maeda, M., Matsui, T., Imamuram, M., Tsukitani, S., and Tsukita, S. 1999. Expression level, subcellular distribution and p-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins. *Oncogene* **18**: 4788-4797.
- McCartney, B.M. and Fehon, R.G. 1996. Distinct cellular and subcellular patterns of expression imply distinct functions for the *Drosophila* homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. *J. Cell Biol.* **133**: 843-852.
- McClatchey, A.I., Saotome, I., Ramesh, V., Gusella, J.F., and Jacks, T. 1997. The *Nf2* tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. *Genes & Dev.* **11**: 1253-1265.
- McClatchey, A.I., Saotome, I., Mercer, K., Crowley, D., Gusella, J.F., Bronson, R.T., and Jacks, T. 1998. Mice heterozygous for a mutation at the *Nf2* tumor suppressor locus develop a range of highly metastatic tumors. *Genes & Dev.* **12**: 1121-1133.
- Morrison, H., Sherman, L.S., Legg, J., Banine, F., Isacke, C., Haipek, C.A., Gutmann, D.H., Ponta, H., and Herrlich, P. 2001. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. *Genes & Dev.* **15**: 968-980.
- Nagafuchi, A. 2001. Molecular architecture of AJs. *Curr. Opin. Cell Biol.* **13**: 600-603.
- Nollet, F., Berx, G., and van Roy, F. 2000. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. *Mol. Cell. Biol. Res. Comm.* **2**: 77-85.
- Obremski, V.J., Hall, A.M., and Fernandez-Valle, C. 1998. Merlin, the neurofibromatosis type 2 gene product, and  $\beta$ 1 integrin associate in isolated and differentiating Schwann cells. *J. Neurobiol.* **37**: 487-501.
- Pelton, P.D., Sherman, L.S., Rizvi, T.A., Marchionni, M.A., Wood, P., Friedman, R.A., and Ratner, N. 1998. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. *Oncogene* **17**: 2195-2209.
- Perez-Moreno, M., Jamora, C., and Fuchs, E. 2003. Sticky busi-

- ness. Orchestrating cellular signals at adherens junctions. *Cell* **112**: 535-548.
- Quinlan, M.P. and Hyatt, J.L. 1999. Establishment of the circumferential actin filament network is a prerequisite for localization of the cadherin-catenin complex in epithelial cells. *Cell Growth Diff.* **10**: 839-854.
- Sako, Y., Nagafuchi, A., Tsukita, S., Takeichi, M., and Kasumi, A. 1998. Cytoplasmic regulation of the movement of E-cadherin on the free cell surface as studied by optical tweezers and single particle tracking: Corraling and tethering by the membrane skeleton. *J. Cell Biol.* **140**: 1227-1240.
- Shaw, R.J., McClatchey, A.I., and Jacks, T. 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. *J. Biol. Chem.* **273**: 7757-7764.
- Shaw, R.J., Paez, J.G., Curto, M., Yaktine, A., Pruitt, W.M., Saotome, I., O'Bryan, J.P., Gupta, V., Ratner, N., Der, C.J., et al. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. *Dev. Cell* **1**: 63-72.
- Sun, C.-X., Robb, V.A., and Gutmann, D.H. 2002. Protein tumor suppressors: Getting a FERM grip on growth regulation. *J. Cell Sci.* **115**: 3991-4000.
- Vaezi, A., Bauer, C., Vasioukhin, V., and Fuchs, E. 2002. Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. *Dev. Cell* **3**: 367-381.
- Vasioukhin, V., Bauer, C., Yin, M., and Fuchs, E. 2000. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. *Cell* **100**: 209-219.
- Vasioukhin, V., Bauer, C., Degenstein, L., Wise, B., and Fuchs, E. 2001. Hyperproliferation and defects in epithelial polarity upon conditional ablation of  $\alpha$ -catenin in skin. *Cell* **104**: 605-617.
- Yap, A.S. and Kovacs, E.M. 2003. Direct cadherin-activated cell signaling: A view from the plasma membrane. *J. Cell Biol.* **160**: 11-16.
- Yonemura, S., Itoh, M., Nagafuchi, A., and Tsukita, S. 1995. Cell-to-cell adherens junction formation and actin filament organization: Similarities and differences between non-polarized fibroblasts and polarized epithelial cells. *J. Cell Sci.* **108**: 127-142.